Combined General Meeting of November 27, 2025 - Availability of the preparatory documents

Daix (France), New York City (New York, United States), November 6,  2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of November 27, 2025.

Shareholders are invited to participate in the Combined General Meeting that will be held on November 27^th at
9 a.m. CEST at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Paris (France).

The preliminary notice of meeting comprising the agenda and the draft resolutions, as well as information on how to attend and vote at the Combined General Meeting, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n°126 of October 20, 2025 and a translation was filed with the Securities and Exchange Commission on October 20, 2025.

This meeting is convened in particular to approve, following the appointment of a new Chief Executive Officer announced on October 1, 2025, (i) the terms of the compensation policy applicable to the new Chief Executive Officer, Mr. Andrew Obenshain¹, (ii) the terms of the agreement setting out the conditions of departure of the former Chief Executive Officer, Mr. Frédéric Cren, and to authorize the Board of Directors to partially waive the presence and performance conditions attached to certain free share plans granted to Mr. Cren, beyond the provisions of the compensation policy applicable to Mr. Cren, in recognition of his significant contributions to the Company². Mr. Frédéric Cren's term of office ended on September 30, 2025. He is working with Mr. Obenshain to ensure a smooth transition and continuity of the Company's strategic priorities.

Information and documents pertaining to the Combined General Meeting are available on the Company's website (www.inventivapharma.com, section "Investors" / "Shareholder Meetings").

In accordance with articles R. 225-83 and R. 225-89 of the French Commercial Code, documents that must be available for the shareholders for the purpose of general meetings will be available at the Company's registered office, 50, Rue de Dijon, 21121 Daix (France), the fifteenth day prior to the Combined General Meeting.

Documents listed in Article R.22-10-23 of the French Commercial Code are available on Inventiva’s website mentioned above as of tomorrow, the twenty-first day that precedes the General Meeting.